Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03Christian Taverna, Michele Ghielmini, Giovanni Martinelli et al.|Journal of Clinical Oncology|2015Cited by 63
Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapyEmanuele Zucca, Eva Kimby, Stéphanie Rondeau et al.|Blood|2019Cited by 61
IELSG30 phase 2 trial: intravenous and intrathecal CNS prophylaxis in primary testicular diffuse large B-cell lymphomaAnnarita Conconi, Emanuele Zucca, Annalisa Chiappella et al.|Blood Advances|2024Cited by 29
Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trialAlden A. Moccia, Emanuele Zucca, Christian Taverna et al.|Blood Advances|2020Cited by 25
Rituximab Maintenance Treatment For a Maximum Of 5 Years In Follicular Lymphoma: Results Of The Randomized Phase III Trial SAKK 35/03Christian Taverna, Michele Ghielmini, Giovanni Martinelli et al.|Blood|2013Cited by 13